U.S. — According to Vitruvias Therapeutics, no reports of adverse or harmful health events related to the recall have been reported. The company warned patients not to stop taking the medication without speaking to their doctor.

Why It Matters

Taking superpotent thyroid tablets can lead to hyperthyroidism, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances. Elderly and pregnant patients are at greatest risk from excess levels of thyroid hormones, which can lead to cardiac issues and higher rates of maternal fetal complications.

Timeline

The recalled tablets were distributed nationwide from Jan. 31, 2025, to Sept. 30, 2025. Vitruvias Therapeutics issued a nationwide recall of one lot of Thyroid Tablets USP 30 mg due to potential superpotency on August 24, 2025. Vitruvias Therapeutics initiated the voluntary recall on August 21, and the FDA published the announcement on August 24, 2026.

What's New

Vitruvias Therapeutics released 3,655 units and sold 1,955 units of the recalled lot. Vitruvias Therapeutics is arranging for the recalled tablets to be destroyed.

No reports of adverse or harmful health events related to the recall have been reported, according to Vitruvias Therapeutics. Vitruvias Therapeutics is notifying wholesalers by email and phone to discontinue distribution of the product. Vitruvias Therapeutics warned patients not to stop taking the medication without speaking to their doctor. The recalled product is Lot 504950 of 30 mg Thyroid Tablets.